Vosevi (Sofosbuvir/Velpatas/Voxilaprev) Patent Expiration, LOE Window & CMS Spending
Vosevi (Sofosbuvir/Velpatas/Voxilaprev) by Gilead Sciences: FDA Orange Book core substance LOE 2034-07-17 (last listed 2037-12-01), 0 AB generics, $84.5M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Gilead Sciences |
| FDA Application & Pathway | N209195 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2034-07-17 |
| Last Listed Patent or Exclusivity Date | 2037-12-01 |
| Orange Book Patents (*PED Extensions) | 32 patents (14 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $84.5M |
| 2024 Medicare Part D Spend | $45.2M |
| 2024 Medicaid Spend | $39.4M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Gilead Sciences across sibling Meru public-data platforms.